Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 22Salivary Gland Neoplasms 3Prostate Adenocarcinoma 2Neoplasm Metastasis 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Primary Dysautonomias 1Patient Compliance 1PSA Level Greater Than Two 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Castrate Sensitive Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Letrozole 5Fulvestrant 5trastuzumab deruxtecan 3Injections 3toripalimab 2sacituzumab govitecan 2palbociclib 2elacestrant 2abemaciclib 2Anastrozole 2AZD9833 2ribociclib 1pyrotinib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1Vinorelbine 1Selective Estrogen Receptor Modulators 1Ritonavir 1RAD1901 1Paclitaxel 1Lead 1Itraconazole 1Goserelin 1Gonadotropin-Releasing Hormone 1Everolimus 1Docetaxel 1Bevacizumab 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × Goserelin × 1 year × Clear all
NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

EQRx International, Inc.

Phase 2 Terminated
100 enrolled 14 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡